We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Stool DNA Analysis Tracks Disease Activity in IBD

By LabMedica International staff writers
Posted on 11 May 2026

Inflammatory bowel disease (IBD) affects an estimated 6–8 million people worldwide and is commonly monitored through colonoscopy and stool testing. More...

Because disease activity can fluctuate, laboratories need noninvasive markers that reflect intestinal inflammation in real time. Human DNA in feces has traditionally been treated as background rather than a measurable analyte. New findings show that cell-of-origin analysis of fecal human DNA can help index disease activity in both pediatric and adult IBD.

Researchers at the Hebrew University of Jerusalem, with Shaare Zedek Medical Center, outline a stool-based approach that profiles human DNA fragments using methylation to determine their cellular origin. The analysis shows that DNA derived from neutrophils dominates the human signal in stool from patients with IBD, rather than colon epithelial DNA as previously assumed. By explicitly measuring host DNA alongside microbial features, the method provides a composite view of gut inflammation.

The study, published in Microbiome, examined pediatric patients in Israel and adult patients in the Netherlands, demonstrating consistent results across ages. Neutrophil DNA levels in stool correlated with established clinical markers, including fecal calprotectin. The authors also introduce a Neutrophil-to-Epithelial Ratio (NER), which more effectively distinguishes remission from active disease than assessing either component alone.

In addition to correlation with current markers, combining human DNA signals with microbiome data enabled machine learning models to predict IBD and differentiate Crohn’s disease from ulcerative colitis. The investigators note that calprotectin assays have detection limits that can hinder assessment in the most severe cases, whereas host DNA profiling captures real-time immune activity. Collectively, the findings suggest a path toward noninvasive, longitudinal monitoring of disease flares and treatment response using a simple stool sample.

“For too long, the human DNA found in stool samples was treated as biological ‘noise’ that we filtered out to focus on microbial data,” said Prof. Moran Yassour, from Hebrew University.

“Our findings show that this DNA contains valuable, unappreciated information, reflecting the immune system’s activity in real time. By analyzing both the human and microbial components together, we can gain a much clearer picture of what is happening in the gut.”

Related Links
Hebrew University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.